USAQOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
QHSLab, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.32+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $7.38M
- P/E (TTM)
- –
- Dividend yield
- –
QHSLab, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integrated Service Program [Member] | $491.40K | $374.50K | $335.63K | $359.38K | $263.63K | $162.50K | $194.01K | $161.75K | $160.45K | $127.00K | $85.22K | $71.60K | 58.0% | +86.4% |
| Allergy Diagnostic Kit Sales [Member] | $196.06K | $228.77K | $144.19K | $216.36K | $197.64K | $264.91K | $184.81K | $220.12K | $190.99K | $237.07K | $129.86K | $148.91K | 23.1% | -0.8% |
| Immunotherapy Treatment Sales [Member] | $93.97K | $91.07K | $139.07K | $131.48K | $119.89K | $97.33K | $166.64K | $63.87K | $92.48K | $86.33K | $75.48K | $88.93K | 11.1% | -21.6% |
| Clinical Study Revenue [Member] | $29.70K | – | $44.55K | $0 | $0 | $89.10K | $59.40K | $74.25K | – | – | – | – | 3.5% | – |
| Training And Other Revenue [Member] | $18.78K | $10.76K | $20.90K | $2.52K | $4.95K | $12.32K | $3.24K | $3.30K | $5.95K | $9.86K | $1.43K | $3.23K | 2.2% | +279.7% |
| Shipping and Handling [Member] | $10.91K | $11.64K | $10.15K | $11.46K | $10.09K | $9.97K | $8.90K | $8.17K | $8.86K | $9.96K | $6.17K | $7.81K | 1.3% | +8.2% |
| Subscription Revenue [Member] | $6.67K | $11.95K | $9.32K | $15.88K | $9.25K | $9.29K | $8.99K | $12.83K | $14.34K | $18.37K | $16.87K | $15.92K | 0.8% | -28.0% |
By region
From the segment and revenue-disaggregation notes of QHSLab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.